Heres What Analysts Are Forecasting For NeuroPace, Inc. After Its Third-Quarter Results
| NPCE Stock | USD 11.14 0.50 4.70% |
About 58% of all Neuropace's shareholders are looking to take a long position. The analysis of overall sentiment of trading Neuropace stock suggests that some investors are interested at this time. The current market sentiment, together with Neuropace's historical and current headlines, can help investors time the market. In addition, many technical investors use Neuropace stock news signals to limit their universe of possible portfolio assets.
Neuropace |
A week ago, NeuroPace, Inc. came out with a strong set of quarterly numbers that could potentially lead...
Read at simplywall.st
 |
Neuropace Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Neuropace can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Neuropace Fundamental Analysis
We analyze Neuropace's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Neuropace using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Neuropace based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Probability Of Bankruptcy
Probability Of Bankruptcy Comparative Analysis
Neuropace is currently under evaluation in probability of bankruptcy category among its peers. Probability Of Bankruptcy is a relative measure of the likelihood of financial distress. For stocks, the Probability Of Bankruptcy is the normalized value of Z-Score. For funds and ETFs, it is derived from a multi-factor model developed by Macroaxis. The score is used to predict the probability of a firm or a fund experiencing financial distress within the next 24 months. Unlike Z-Score, Probability Of Bankruptcy is the value between 0 and 100, indicating the firm's actual probability it will be financially distressed in the next 2 fiscal years.
Neuropace Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Neuropace stock to make a market-neutral strategy. Peer analysis of Neuropace could also be used in its relative valuation, which is a method of valuing Neuropace by comparing valuation metrics with similar companies.
Peers
Neuropace Related Equities
| ANIK | Anika Therapeutics | 1.81 | ||||
| ELMD | Electromed | 1.78 | ||||
| ITGR | Integer Holdings | 1.06 | ||||
| CNMD | CONMED | 0.98 | ||||
| AORT | Artivion | 0.65 | ||||
| SRDX | SurModics | 0.53 | ||||
| KIDS | Orthopediatrics Corp | 0.58 | ||||
| GKOS | Glaukos Corp | 0.96 | ||||
| IRMD | Iradimed | 1.26 | ||||
| CVRX | CVRx | 2.01 | ||||
| OFIX | Orthofix Medical | 2.23 | ||||
| LUNG | Pulmonx Corp | 2.79 | ||||
| FNA | Paragon 28 | 3.09 | ||||
| NVRO | Nevro Corp | 4.01 |
Complementary Tools for Neuropace Stock analysis
When running Neuropace's price analysis, check to measure Neuropace's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Neuropace is operating at the current time. Most of Neuropace's value examination focuses on studying past and present price action to predict the probability of Neuropace's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Neuropace's price. Additionally, you may evaluate how the addition of Neuropace to your portfolios can decrease your overall portfolio volatility.
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. |